MYADM and pulmonary arterial hypertension: Recently, researchers from the Peking Union Medical College have also described that the miR-182-3p/MYADM axis either inhibits pulmonary artery SMC proliferation via a KLF4/p21-dependent mechanism, or balances the BMP- and TGF-β signaling pathways in an SMC/EC-crosstalk-associated manner in pulmonary hypertension (Sun et al., 2020) (Bai et al., 2021).